Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 169, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2021.103571
Keywords
Pancreatic ductal adenocarcinoma; Adjuvant chemotherapy; Neoadjuvant chemotherapy; Patient-reported outcomes; Healthcare management; Locally advanced pancreatic cancer; Borderline Resectable pancreatic cancer
Categories
Funding
- Celgene
Ask authors/readers for more resources
This review addresses the main unanswered questions about the clinical management of pancreatic ductal adenocarcinoma, aiming to provide practical decision support for physicians.
The prognosis of pancreatic ductal adenocarcinoma is still the worst among solid tumors. In this review, a panel of experts addressed the main unanswered questions about the clinical management of this disease, with the aim of providing practical decision support for physicians. On the basis of the evidence available from the literature, the main topics concerning pancreatic cancer are discussed: the diagnosis, as the need for a pathological characterization and the role for germ-line and somatic molecular profiling; the therapeutic management of resectable disease, as the role of upfront surgery or neoadjuvant chemotherapy, the post-operative restaging and the optimal timing foradjuvant chemotherapy, the management of the borderline resectable and locally advanced disease; the metastatic disease and the role of surgery for the management of patients with isolated metastasis and the use of biomarkers of metastatic potential; the role of supportive care and the healthcare management of pancreatic ductal adenocarcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available